Tradestie Institutional Equity Comparison Engine

IONS vs ALNY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ALNY Overall Edge

ALNY Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alnylam Pharmaceuticals, Inc. (ALNY) driven by superior Valuation, Growth & Margin, Momentum & Technical while IONS counters with relative strength in Options & Structure. Fundamentally, IONS trades at 90.9x Forward P/E with -58.8% operating margin (+54.9% YoY revenue) versus ALNY at 15.2x Forward P/E and 19.5% operating margin (+16.7% YoY). In options structure, IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against ALNY sits in BREAKDOWN (29th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ALNY
IONS 90.9x vs ALNY 15.2x Fwd P/E
Growth & Margin Winner ALNY
Op Margin -58.8% vs 19.5% ยท YoY +54.9% vs +16.7%
Momentum & Technical Winner ALNY
1Y -59.1% vs -64.8% ยท 52W Pos 2% vs 3%
Options & Structure Winner IONS
BREAKDOWN (17th %ile IV) vs BREAKDOWN (29th %ile IV)
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
1M Return -33.48%
1Y Return -59.1%
Forward P/E 90.9x
Unified AI Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
ALNY NASDAQ
Alnylam Pharmaceuticals, Inc.
Pharmaceutical Preparations
$159.64
-3.27% 1D
Market Cap $21.0B
1M Return -31.14%
1Y Return -64.83%
Forward P/E 15.2x
Unified AI Score
60.1 / 100 BUY
Tech 91.0 Fund 77.0 Flow 67.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IONS -59.1% ALNY -64.83% Spread: +5.73 pp (IONS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period IONS Revenue ALNY Revenue IONS Op. Margin ALNY Op. Margin Margin Edge
FY2018 $600M $70M -10.2% -1087.6% IONS
FY2019 $1.12B $220M 32.6% -427.5% IONS
FY2020 $730M $490M -23.6% -168.1% IONS
FY2021 $810M $840M -3.7% -83.9% IONS
FY2022 $590M $1.04B -69.8% -75.7% IONS
FY2023 $790M $1.83B -44.9% -15.4% ALNY
FY2024 $710M $2.25B -67.4% -7.9% ALNY
FY2025 $940M $3.71B -40.4% 13.5% ALNY

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IONS (3) vs ALNY (7)
Institutional Metric IONS ALNY Criterion Row Winner
Market Capitalization Scale $4.7B $21.0B Larger Scale ALNY
Trailing P/E Ratio Valuation 90.9x 7.9x Lower Multiple ALNY
Forward P/E Ratio Valuation 90.9x 15.2x Lower Multiple ALNY
Revenue Growth (YoY) Growth +54.9% +16.7% Higher Growth IONS
Operating Margin (TTM) Profitability -58.8% 19.5% Higher Margin ALNY
Net Profit Margin Profitability -56.9% 52.8% Higher Margin ALNY
Return on Equity (ROE) Capital Efficiency -108.0% 138.1% Higher ROE ALNY
52-Week Range Position Momentum 2% ($27โ€“$87) 3% ($149โ€“$477) Stronger Trend ALNY
Beta / 30D Volatility Risk Regime 0.18ฮฒ ยท 86% Vol 0.54ฮฒ ยท 96% Vol Lower Realized Risk IONS
Unified Institutional Score Composite Signal 63.9 / 100 (BUY) 60.1 / 100 (BUY) Higher Composite IONS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IONS vs ALNY Buy Guide
IONS BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live IONS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ALNY BREAKDOWN
52d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 29th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ALNY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IONS nor ALNY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.